{"groups":[{"description":"During Chemotherapy:\n\nPatients received durvalumab (D) 1500 milligrams (mg) in combination with tremelimumab (T) 75 mg intravenous (IV) infusion every 3 weeks (Q3W) for 4 doses/cycles (Weeks 0, 3, 6 and 9). For chemotherapy (EP), patients received etoposide (80-100 mg/meters squared \\[m\\^2\\]) with either carboplatin (area under the curve 5-6) or cisplatin (75-80 mg/m\\^2) IV infusion Q3W for 4 doses/cycles (Weeks 0, 3, 6 and 9).\n\nPost-Chemotherapy:\n\nPatients then continued to receive durvalumab 1500 mg IV infusion every 4 weeks (Q4W) from Week 12 until progressive disease (PD), unless there was unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met. Patients also received an additional dose of tremelimumab 75 mg IV infusion post-chemotherapy (in combination with durvalumab) at Week 16 if they completed all 4 doses of durvalumab + tremelimumab during chemotherapy.","id":"FG000","title":"All Patients: D + T + EP"},{"description":"During Chemotherapy:\n\nPatients received durvalumab (D) 1500 mg IV infusion Q3W for 4 doses/cycles (Weeks 0, 3, 6 and 9). For chemotherapy (EP), patients received etoposide (80-100 mg/m\\^2) with either carboplatin (area under the curve 5-6) or cisplatin (75-80 mg/m\\^2) IV infusion Q3W for 4 doses/cycles (Weeks 0, 3, 6 and 9).\n\nPost-Chemotherapy:\n\nPatients then continued to receive durvalumab 1500 mg IV infusion Q4W from Week 12 until PD, unless there was unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.","id":"FG001","title":"All Patients: D + EP"},{"description":"For chemotherapy (EP), patients received etoposide (80-100 mg/m\\^2) with either carboplatin (area under the curve 5-6) or cisplatin (75-80 mg/m\\^2) IV infusion Q3W for 4 doses/cycles (Weeks 0, 3, 6 and 9). An additional 2 doses of EP (at Weeks 12 and 15) could be given at the investigators' discretion if clinically indicated.","id":"FG002","title":"All Patients: EP"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"15"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"270"},{"groupId":"FG001","numSubjects":"269"},{"groupId":"FG002","numSubjects":"296"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"329"},{"groupId":"FG001","numSubjects":"328"},{"groupId":"FG002","numSubjects":"330"}],"comment":"Randomized in overall study","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"268"},{"groupId":"FG001","numSubjects":"268"},{"groupId":"FG002","numSubjects":"269"}],"type":"Randomized and Included in Global Cohort Analysis"},{"achievements":[{"groupId":"FG000","numSubjects":"266"},{"groupId":"FG001","numSubjects":"265"},{"groupId":"FG002","numSubjects":"266"}],"type":"Received Treatment in Global Cohort"},{"achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"61"},{"groupId":"FG002","numSubjects":"62"}],"type":"Randomized and Included in China Cohort Analysis"},{"achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"61"},{"groupId":"FG002","numSubjects":"62"}],"type":"Received Treatment in China Cohort"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Included in Both Cohorts (Global + China)"},{"achievements":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"56"},{"groupId":"FG002","numSubjects":"31"}],"type":"Ongoing Study at Global Cohort Final Analysis Data Cut-off (DCO)"},{"achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"7"}],"type":"Ongoing Study at China Cohort Second (Final) Analysis DCO"},{"achievements":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"52"},{"groupId":"FG002","numSubjects":"18"}],"comment":"Ongoing in overall study at long-term follow-up (LTFU) analysis DCO","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"278"},{"groupId":"FG001","numSubjects":"276"},{"groupId":"FG002","numSubjects":"312"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients were randomized in a 1:1:1 ratio to receive treatment with durvalumab + tremelimumab + etoposide and platinum-based chemotherapy (EP), durvalumab + EP or EP alone. 987 participants were randomized in the study overall. Patients included in both cohorts for Started, Completed and Reasons for Not Completed are not double-counted for participant flow.","recruitmentDetails":"Study was conducted in 209 study centers across 23 countries. It included a global cohort (805 patients) and China cohort (188 patients). China cohort comprised 6 patients also in the global cohort and a further 182 patients randomized after end of global cohort recruitment. Results of the global and China cohorts were reported separately."}